Replies to post #227507 on Biotech Values

[tony111]

LoL with Loxo-305 being the competitor, ARQL has no chance going up against Lily. ARQL CEO is a good CEO to sell the company decisively. Too bad I sold ARQL when the stock tanked last month on release of Lox-305 abstract.